Comparative Pharmacology
Head-to-head clinical analysis: EDURANT PED versus RESCRIPTOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EDURANT PED versus RESCRIPTOR.
EDURANT PED vs RESCRIPTOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Edurant PED is a non-nucleoside reverse transcriptase inhibitor (NNRTI) of HIV-1. It binds to reverse transcriptase, causing a conformational change that inhibits the enzyme's RNA-dependent and DNA-dependent DNA polymerase activities, thereby blocking viral replication.
Non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds directly to HIV-1 reverse transcriptase, causing conformational change and inhibiting RNA-dependent DNA polymerase activity.
25 mg orally once daily with a meal.
400 mg orally three times daily.
None Documented
None Documented
Terminal elimination half-life is approximately 50 hours (range 34-73 h). This long half-life supports once-daily dosing and allows for sustained plasma concentrations.
Terminal elimination half-life is 2.5–4.5 hours in adults. This short half-life necessitates twice-daily dosing. In patients with hepatic impairment, half-life may be prolonged.
Rilpivirine is primarily metabolized by CYP3A4; after oral administration, approximately 85% of the dose is recovered in feces (mainly as unchanged drug and metabolites) and 6% in urine. Less than 1% is excreted unchanged in urine.
Renal: 51% (unchanged drug) and 44% (glucuronide metabolite); biliary/fecal: <5%. Total recovery in urine is approximately 95%.
Category C
Category C
NNRTI Antiretroviral
NNRTI Antiretroviral